» Articles » PMID: 38501230

Plasma Ceramides and Other Sphingolipids in Relation to Incident Prediabetes in a Longitudinal Biracial Cohort

Overview
Specialty Endocrinology
Date 2024 Mar 19
PMID 38501230
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Sphingolipids are linked to the pathogenesis of type 2 diabetes.

Objective: To test the hypothesis that plasma sphingolipid profiles predict incident prediabetes.

Design: A case-control study nested in the Pathobiology of Prediabetes in a Biracial Cohort study, a 5-year follow-up study.

Setting: Academic health center.

Participants: Normoglycemic adults enrolled in the Pathobiology of Prediabetes in a Biracial Cohort study. Assessments included oral glucose tolerance test, insulin sensitivity, and insulin secretion. Participants with incident prediabetes were matched in age, sex, and ethnicity with nonprogressors.

Interventions: We assayed 58 sphingolipid species (ceramides, monohexosyl ceramides, sphingomyelins, and sphingosine) using liquid chromatography/tandem mass spectrometry in baseline plasma levels from participants and determined association with prediabetes risk.

Main Outcome Measure: The primary outcome was progression from normoglycemia to prediabetes, defined as impaired fasting glucose or impaired glucose tolerance.

Results: The mean age of participants (N = 140; 50% Black, 50% female) was 48.1 ± 8.69 years, body mass index 30.1 ± 5.78 kg/m2, fasting plasma glucose 92.7 ± 5.84 mg/dL, and 2-hour plasma glucose 121 ± 23.3 mg/dL. Of the 58 sphingolipid species assayed, higher ratios of sphingomyelin C26:0/C26:1 (OR, 2.73 [95% CI, 1.172-4.408], P = .015) and ceramide C18:0/C18:1 (OR, 1.236 [95% CI, 1.042-1.466], P = .015) in baseline plasma specimens were significantly associated with progression to prediabetes during the 5-year follow-up period, after adjustments for age, race, sex, body mass index, fasting plasma glucose, 2-hour plasma glucose, insulin sensitivity, and insulin secretion.

Conclusion: We conclude that the saturated-to-monounsaturated ratios of long-chain ceramide C18:0/C18:1 and very-long-chain sphingomyelin C26:0/C26:1 are potential biomarkers of prediabetes risk among individuals with parental history of type 2 diabetes.

Citing Articles

Sphingolipids Demystify Prediabetic Risk.

Kasumov T J Clin Endocrinol Metab. 2024; 110(2):e540-e541.

PMID: 38856104 PMC: 11747671. DOI: 10.1210/clinem/dgae274.

References
1.
Wilson P, Meigs J, Sullivan L, Fox C, Nathan D, DAgostino Sr R . Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007; 167(10):1068-74. DOI: 10.1001/archinte.167.10.1068. View

2.
Mandal N, Asuzu P, Stentz F, Wan J, Dagogo-Jack S . Ceramides and other sphingolipids as predictors of incident dysglycemia (CASPID): Design, methods, and baseline characteristics. Exp Biol Med (Maywood). 2023; 248(16):1393-1402. PMC: 10657588. DOI: 10.1177/15353702231184228. View

3.
Sokolowska E, Blachnio-Zabielska A . The Role of Ceramides in Insulin Resistance. Front Endocrinol (Lausanne). 2019; 10:577. PMC: 6712072. DOI: 10.3389/fendo.2019.00577. View

4.
Bartke N, Hannun Y . Bioactive sphingolipids: metabolism and function. J Lipid Res. 2008; 50 Suppl:S91-6. PMC: 2674734. DOI: 10.1194/jlr.R800080-JLR200. View

5.
Hooper L, Martin N, Jimoh O, Kirk C, Foster E, Abdelhamid A . Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020; 5:CD011737. PMC: 7388853. DOI: 10.1002/14651858.CD011737.pub2. View